Merck, a leading science and technology company, today announced the presentation of detailed results from Cohort B of the global Phase 2 WILLOW study (NCT05162586) evaluating enpatoran, an ...

Cohort A focused on patients with CLE or SLE with active lupus rash and evaluated organ-specific disease activity using the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity ...

Clotting is a serious complication of systemic lupus erythematosus (SLE) for several reasons. First, clotting can cause persistent disability and death or fetal loss in pregnant women. Second, the ...

BARCELONA -- The oral drug deucravacitinib (Sotyktu) passed what is probably its final test as a treatment for psoriatic arthritis (PsA), demonstrating superiority over placebo for most of its ...

Immunovant faces high R&D costs, limited cash runway, and unproven clinical edge despite pipeline progress and deeper IgG ...

Merck KGaA has shed more light on the failure of its lupus drug in one cohort of patients, while pointing to secondary ...

Cohort B of the Phase 2 study indicates all doses of enpatoran were associated with higher BICLA response rates compared with placebo, though the ...

Topical calcineurin inhibitors in cutaneous lupus erythematosus In the management of cutaneous lupus erythematosus (CLE), topical calcineurin inhibitors have recently been established as the ...

– 7 of 8 myositis patients achieved clinically meaningful TIS responses after discontinuation of all immunomodulators, while off or actively tapering steroids; responses were sustained ...